V-RULES: Real-World Effectiveness and Safety of CPX-351 for First-Line Treatment of Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes in the US
Publication date: Available online 19 November 2026 Source: Clinical Lymphoma Myeloma and Leukemia Author(s): Thomas W. LeBlanc, Catherine Lai, Amir Ali, Onyee Chan, Doria Cole, Melisa Stricherz, Jesus D. Gonzalez-Lugo, Kristin L. Koenig, Mimi Lo, Matthew J. Newman, Saemi Park, Giuseppe Piccoli, Helen Chen, Daniel Cuadras, Montse Pedrós, Mark Lynam, Charlotte B. Wagner, Amanda Lopez, George Yaghmour, Eunice S. Wang
V-RULES: Real-World Effectiveness and Safety of CPX-351 for First-Line Treatment of Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes in the US. // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026040401?dgcid=rss_sd_all
V-RULES: Real-World Effectiveness and Safety of CPX-351 for First-Line Treatment of Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes in the US. Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026040401?dgcid=rss_sd_all
“V-RULES: Real-World Effectiveness and Safety of CPX-351 for First-Line Treatment of Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes in the US.” Clinical Lymphoma, Myeloma & Leukemia.
@article{article99929,
title = {V-RULES: Real-World Effectiveness and Safety of CPX-351 for First-Line Treatment of Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes in the US},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026040401?dgcid=rss_sd_all}
}